Securities Code: 002432 Securities Abbreviation: Jiuan Medical Announcement No.: 2026-013
Tianjin Jiuan Medical Electronic Co., Ltd. Announcement on Participating in Fund Subscription and Related Party Transaction
The Company and all members of the Board of Directors guarantee that the information disclosed is true, accurate, and complete, and that there are no false records, misleading statements, or major omissions.
Special Reminder:
- Name of the investment target: Tianjin Haitang Tonghui Venture Capital Partnership (Limited Partnership) (hereinafter referred to as "Haitang Tonghui Fund")
- Investment amount: The Company will invest RMB 103 million of its own funds in the Haitang Tonghui Fund (subject to the actual amount invested). The total scale of the fund is RMB 412.01 million (subject to the actual amount raised). The Company intends to act as one of the limited partners (LP) to make a financial investment. The funds raised by the Haitang Tonghui Fund are intended to be specifically used for the investment in the target project. The Company will indirectly invest RMB 100 million in the target project through the Haitang Tonghui Fund (subject to the actual amount invested), and will enjoy investment income and bear investment risks within the investment amount.
- This investment will not have a significant impact on the Company's current operating performance and financial indicators.
- This investment has no principal protection or minimum return commitment. The investment target is susceptible to market conditions, industry policies, and regulatory factors, which may affect the value of the fund units and even lead to investment failure and loss risks. This investment is characterized by a long investment recovery period and low liquidity. The investment process may be affected by various factors such as macroeconomic conditions, industry cycles, market competition, policy environment, and the operating management of the proposed investment projects, and there is a risk that expected returns may not be realized after investment. The Company will closely monitor the subsequent progress of this investment and fulfill information disclosure obligations in a timely manner in accordance with relevant laws and regulations. Investors are urged to invest rationally and be aware of investment risks.
- Sun Weijun, an independent director of the Company, indirectly holds equity in the target project of this fund investment. After careful consideration, this investment matter is deliberated as a related party transaction and requires the approval of more than half of the independent directors before proceeding with the board of directors' deliberation process. This investment matter does not constitute a major asset restructuring as stipulated in the "Measures for the Administration of Major Asset Restructuring of Listed Companies."